Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.

Mack Roach; Zachary Gostout; Patricia Zawisny; Avi S. Retter; Gerald H. Sokol; Steve Hoffman; Giuseppe Del Priore

doi:10.1200/JCO.2018.36.6_SUPPL.175

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.

Mack Roach
, Zachary Gostout
, Patricia Zawisny
, Avi S. Retter
, Gerald H. Sokol
, Steve Hoffman
, Giuseppe Del Priore

University of California, San Francisco
Tyme Technologies, Inc., New York, NY;
Eastchester Center for Cancer Care, Bergenfield, NJ;
Florida Cancer Institute New Hope, Hudson, FL;
Morehouse School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.6_SUPPL.175
State	Published - Feb 26 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2018.36.6_SUPPL.175License: Unspecified

Cite this

@article{7087739ccacd4c51837d4ddd8ae71947,

title = "Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.",

author = "Mack Roach and Zachary Gostout and Patricia Zawisny and Retter, \{Avi S.\} and Sokol, \{Gerald H.\} and Steve Hoffman and \{Del Priore\}, Giuseppe",

note = "175 Background: Despite toxicity and no clear survival benefit, non-metastatic recurrent prostate cancer (nmPC) is typically treated with androgen deprivation therapy (ADT). SM88 is a relatively non-toxic novel combination therapy (amino acid analogue, CYP3a4 inducer, mTOR inhibitor and catalyst) based on the Warburg effect, with activity in a variety of cancers including prostate (JCO 2017 35, e16567).",

year = "2018",

month = feb,

day = "26",

doi = "10.1200/JCO.2018.36.6\_SUPPL.175",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.

AU - Roach, Mack

AU - Gostout, Zachary

AU - Zawisny, Patricia

AU - Retter, Avi S.

AU - Sokol, Gerald H.

AU - Hoffman, Steve

AU - Del Priore, Giuseppe

N1 - 175 Background: Despite toxicity and no clear survival benefit, non-metastatic recurrent prostate cancer (nmPC) is typically treated with androgen deprivation therapy (ADT). SM88 is a relatively non-toxic novel combination therapy (amino acid analogue, CYP3a4 inducer, mTOR inhibitor and catalyst) based on the Warburg effect, with activity in a variety of cancers including prostate (JCO 2017 35, e16567).

PY - 2018/2/26

Y1 - 2018/2/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.175

U2 - 10.1200/JCO.2018.36.6_SUPPL.175

DO - 10.1200/JCO.2018.36.6_SUPPL.175

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.

Disciplines

Access to Document

Other files and links

Cite this